Lineage Cell Therapeutics, Inc. (TLV:LCTX)

Lineage Cell Therapeutics Revenue

Lineage Cell Therapeutics had revenue of $3.68M USD in the quarter ending September 30, 2025, a decrease of -2.59%. This brings the company's revenue in the last twelve months to $10.82M, up 24.05% year-over-year. In the year 2024, Lineage Cell Therapeutics had annual revenue of $9.50M with 6.19% growth.

• Revenue (ttm): $10.82M
• Revenue Growth: +24.05%
• P/S Ratio: 38.79
• Revenue / Employee: $140.47K
• Employees: 77
• Market Cap: 1.39B ILS

Revenue Chart

* This company reports financials in USD.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	9.50M	554.00K	6.19%
Dec 31, 2023	8.95M	-5.76M	-39.16%
Dec 31, 2022	14.70M	10.36M	238.70%
Dec 31, 2021	4.34M	2.52M	137.73%
Dec 31, 2020	1.83M	-1.69M	-48.05%
Dec 31, 2019	3.52M	-1.47M	-29.53%
Dec 31, 2018	4.99M	1.53M	44.25%
Dec 31, 2017	3.46M	-2.47M	-41.62%
Dec 31, 2016	5.92M	-1.11M	-15.82%
Dec 31, 2015	7.04M	1.79M	34.17%
Dec 31, 2014	5.24M	810.00K	18.27%
Dec 31, 2013	4.43M	518.67K	13.25%
Dec 31, 2012	3.92M	-518.83K	-11.70%
Dec 31, 2011	4.43M	726.14K	19.58%
Dec 31, 2010	3.71M	1.78M	92.61%
Dec 31, 2009	1.93M	421.38K	28.02%
Dec 31, 2008	1.50M	457.67K	43.75%
Dec 31, 2007	1.05M	-	-